Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17488335 | 0.90 | SCN9A (0.44) | SCN9AKDRTEKSCN7AKCNH2 | |
| SCHEMBL17488103 | 0.84 | SCN9A (0.47) | SCN9AKDRTEKSCN7AKCNH2 | |
| SCHEMBL18965935 | 0.84 | SCN9A (0.44) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL17488274 | 0.82 | RAF1 (0.34) | KDRTEK | |
| SCHEMBL17488003 | 0.78 | SCN9A (0.37) | SCN9AKDRTEKKCNH2 | |
| SCHEMBL17488255 | 0.74 | MCHR1 (0.42) | SCN9AKDRTEKSCN7AKCNH2 | |
| SCHEMBL18965891 | 0.74 | SCN9A (0.44) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL17488159 | 0.73 | RAB9A (0.41) | SCN9AKDRTEK | |
| SCHEMBL17488336 | 0.72 | SCN9A (0.42) | SCN9AKDRTEKSCN7AKCNH2 | |
| SCHEMBL17488301 | 0.72 | CYP3A4 (0.39) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016016421-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2016-02-04 | — | — | WO | disclosed |